149 related articles for article (PubMed ID: 2839612)
1. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas.
Morgan AJ; Mackett M; Finerty S; Arrand JR; Scullion FT; Epstein MA
J Med Virol; 1988 Jun; 25(2):189-95. PubMed ID: 2839612
[TBL] [Abstract][Full Text] [Related]
2. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
Finerty S; Tarlton J; Mackett M; Conway M; Arrand JR; Watkins PE; Morgan AJ
J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes.
Morgan AJ; Finerty S; Lovgren K; Scullion FT; Morein B
J Gen Virol; 1988 Aug; 69 ( Pt 8)():2093-6. PubMed ID: 2841417
[TBL] [Abstract][Full Text] [Related]
4. Vaccination against Epstein-Barr virus: current progress and future strategies.
Epstein MA
Lancet; 1986 Jun; 1(8495):1425-7. PubMed ID: 2872525
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus vaccines.
Morgan AJ
Vaccine; 1992; 10(9):563-71. PubMed ID: 1323899
[TBL] [Abstract][Full Text] [Related]
6. The Leeuwenhoek lecture, 1983. A prototype vaccine to prevent Epstein-Barr virus-associated tumours.
Epstein MA
Proc R Soc Lond B Biol Sci; 1984 Mar; 221(1222):1-20. PubMed ID: 6144103
[TBL] [Abstract][Full Text] [Related]
7. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin.
Ragot T; Finerty S; Watkins PE; Perricaudet M; Morgan AJ
J Gen Virol; 1993 Mar; 74 ( Pt 3)():501-7. PubMed ID: 8383183
[TBL] [Abstract][Full Text] [Related]
8. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine.
Epstein MA; Morgan AJ; Finerty S; Randle BJ; Kirkwood JK
Nature; 1985 Nov 21-27; 318(6043):287-9. PubMed ID: 2999604
[TBL] [Abstract][Full Text] [Related]
9. Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum.
Finerty S; Mackett M; Arrand JR; Watkins PE; Tarlton J; Morgan AJ
Vaccine; 1994 Oct; 12(13):1180-4. PubMed ID: 7839721
[TBL] [Abstract][Full Text] [Related]
10. Latent Epstein-Barr virus infection in cottontop tamarins. A possible model for Epstein-Barr virus infection in humans.
Niedobitek G; Agathanggelou A; Finerty S; Tierney R; Watkins P; Jones EL; Morgan A; Young LS; Rooney N
Am J Pathol; 1994 Oct; 145(4):969-78. PubMed ID: 7943186
[TBL] [Abstract][Full Text] [Related]
11. Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV.
Mackett M; Cox C; Pepper SD; Lees JF; Naylor BA; Wedderburn N; Arrand JR
J Med Virol; 1996 Nov; 50(3):263-71. PubMed ID: 8923292
[TBL] [Abstract][Full Text] [Related]
12. Implications of a vaccine for the prevention of Epstein-Barr virus infection: ethical and logistic considerations.
Epstein MA
Cancer Res; 1976 Feb; 36(2 pt 2):711-4. PubMed ID: 175931
[TBL] [Abstract][Full Text] [Related]
13. Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge.
Cox C; Naylor BA; Mackett M; Arrand JR; Griffin BE; Wedderburn N
J Med Virol; 1998 Aug; 55(4):255-61. PubMed ID: 9661832
[TBL] [Abstract][Full Text] [Related]
14. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines.
Wilson AD; Lövgren-Bengtsson K; Villacres-Ericsson M; Morein B; Morgan AJ
Vaccine; 1999 Mar; 17(9-10):1282-90. PubMed ID: 10195641
[TBL] [Abstract][Full Text] [Related]
15. Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.
Epstein MA; Randle BJ; Finerty S; Kirkwood JK
Clin Exp Immunol; 1986 Mar; 63(3):485-90. PubMed ID: 3011324
[TBL] [Abstract][Full Text] [Related]
16. The Florey lecture, 1986. Vaccine prevention of virus-induced human cancers.
Epstein MA
Proc R Soc Lond B Biol Sci; 1987 Mar; 230(1259):147-61. PubMed ID: 2884667
[TBL] [Abstract][Full Text] [Related]
17. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
[TBL] [Abstract][Full Text] [Related]
18. Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins.
Morgan AJ; Epstein MA; North JR
J Med Virol; 1984; 13(3):281-92. PubMed ID: 6327902
[TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of the Epstein-Barr virus latent membrane protein by a recombinant vaccinia virus.
Stewart JP; Hampson IN; Heinrich HW; Mackett M; Arrand JR
J Gen Virol; 1989 May; 70 ( Pt 5)():1231-7. PubMed ID: 2543776
[TBL] [Abstract][Full Text] [Related]
20. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
Yao QY; Rowe M; Morgan AJ; Sam CK; Prasad U; Dang H; Zeng Y; Rickinson AB
Int J Cancer; 1991 Apr; 48(1):45-50. PubMed ID: 1850382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
